Androgen deprivation therapy: fighting resistance in prostate cancer

Written by Louis Gautier, Future Science Group

androgen deprivation therapy

A recent ex-vivo study from the Institute of Cancer Research (London, UK) has demonstrated the viability of suppressing genetic regulators of the androgen receptor signaling pathway as a way to fight treatment resistance long-term in prostate cancer patients. The collaborative research with the Royal Marsden NHS Foundation (London, UK) was published this week in Cancer Discovery and describes the novel targeted drug, CSS1477, its mechanism of action and its chemical structure. Funding from charities worldwide helped bring the research to fruition, including Movember, the Prostate Cancer Foundation and Cancer Research UK. Androgen deprivation therapy is a mainstay of treatment for...

To view this content, please register now for access

It's completely free